falsefalse

Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 11

Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy

,

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
    EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
    EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
    EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
    EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
    EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
    EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
    EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
    EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
    EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
    Now Viewing
    EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
    EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer

    Related Content:

    Optimizing Therapy for Endometrial Cancer: Recent Data HighlightsNYU Langone's Perlmutter Cancer CenterInsightsGynecologic Oncology
    Dr Sabari on the Activity of Zongertinib in Pretreated, Advanced, HER2-Mutated NSCLC
    First Successful Allogeneic Stem Cell Transplant Using Deceased Donor in Blood Cancer Clinical Trial
    Guidance for Community Oncologists: Expert Advice on Treating Patients With Endometrial Cancer
    x